Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 7, 2010, Pages 1027-1030

  Vogiatzi, Paraskevi ^a   Claudio, Pier Paolo ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

abiraterone acetate; castration resistant prostate cancer; cytochrome P17; docetaxel; MDV3100

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; CYTOCHROME P450 17; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; STEROID;

AGED; ANDROGEN SYNTHESIS; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CASTRATION; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; FLUID RETENTION; HUMAN; HYPERTENSION; HYPOKALEMIA; IN VIVO STUDY; MALE; MOLECULE; MULTICENTER STUDY; NOTE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSTATE CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; STEROID THERAPY; TUMOR CELL;

EID: 77954882149     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.84     Document Type: Note

References (17)

1. Vogiatzi P, Cassone M, Claudio L et al. Targeted therapy for advanced prostate cancer: looking through new lenses. Drug News Perspect. 22(10), 593-601 (2009).
2. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563-4571 (2008).
3. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone- dependence in castration-resistant prostate cancer. Br. J. Cancer 100(5), 671-675 (2009).
4. Attard G, Reid AH, Olmos D et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69(12), 4937-4940 (2009).
5. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration- resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28(9), 1489-1495 (2010).
6. Olmos D, Arkenau HT, Ang JE et al. Circulating tumour cell (CTC) counts as intermediate end points in castration- resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol. 20(1), 27-33 (2009).
7. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16(6), 458-462 (2009).
8. Brodie A, Njar V, Macedo LF et al. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol. Oncol. 27(1), 53-63 (2009).
9. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010).
10. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28(9), 1481-1488 (2010).
11. Pinto-Bazurco Mendieta MA, Negri M et al. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J. Med. Chem. 51(16), 5009-5018 (2008).
12. Hu Q, Negri M, Jahn-Hoffmann K et al. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17a-hydroxylase-17,20-lyase (CYP17) - part II: core rigidification and influence of substituents at the methylene bridge. Bioorg. Med. Chem. 16(16), 7715-7727 (2008).
13. Greco A, Di Benedetto A, Howard CM et al. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol. Ther. 18(2), 295-306 (2010).
14. Drake CG, Antonarakis ES. Update: immunological strategies for prostate cancer. Curr. Urol. Rep. 11(3), 202-207 (2010).
15. Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 11(2), 147-154 (2010).
16. Abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy (NCT00638690) http://clinicaltrials. gov/ct2/show/NCT006 38690?term=NCT00638690&rank=1
17. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (NCT00887198) http://clinicaltrials.gov/ct2/show/NCT00 887198?term=NCT00887198&rank=1